The dopamine receptors of the peripheral cardiovascular system are not a pharmacologically uniform population. A number of studies indicate that they belong to at least two distinct subtypes for which it is proposed to adopt the name DA1- and DA2-dopamine receptors in an attempt to follow the nomenclature presently in fashion for several vascular receptors. Typical DA1-dopamine receptors are those occurring postjunctionally in the renal and mesenteric arterial beds where their stimulation mediates direct smooth muscle relaxation. Typical DA2-dopamine receptors are those present on postganglionic sympathetic neurons (axonal varicosities and perhaps ganglionic cell bodies) where their excitation leads, under appropriate physiological conditions, to a reduction of the neural release of norepinephrine. The latter effect can manifest itself by a passive fall in vascular resistance and heart rate. Other populations of dopamine receptors not yet well characterized pharmacologically but of theoretical interest as additional potential target sites for cardiovascular drugs might be present on nephrons and in the adrenal cortex. Their stimulation can mediate a natriuretic effect and a reduction of aldosterone release, respectively. The pharmacological evidence favoring the subclassification of cardiovascular dopamine receptors into two distinct subtypes is reviewed. Furthermore, the main agonists and antagonists of these receptors and the complexity of their pharmacological profile are mentioned. Part II of this minireview will be dedicated to the description of the sites and mechanisms of the antihypertensive action of dopamine receptor agonists.